nach oben

Clinical Pharmacokinetics

Erschienen in:

23.06.2018 | Letter to the Editor

Author’s Reply to Reith: “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”

verfasst von: Anne van Rongen, Johannes N. van den Anker, Catherijne A. J. Knibbe

Erschienen in: Clinical Pharmacokinetics | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Reith DM, Al-Sallami HS. Comment on: Higher midazolam clearance in obese adolescents compared with morbidly obese adults. Clin Pharmacokinet. 2018. https://doi.org/10.1007/s40262-018-0691-0.CrossRefPubMed

van Rongen A, Brill MJE, Vaughns JD, Valitalo PAJ, van Dongen EPA, van Ramshorst B, et al. Higher midazolam clearance in obese adolescents compared with morbidly obese adults. Clin Pharmacokinet. 2018;57(5):601–11.CrossRefPubMed

Brill MJ, van Rongen A, Houwink AP, Burggraaf J, van Ramshorst B, Wiezer RJ, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet. 2014;53(12):931–41.CrossRefPubMedPubMedCentral

Liu Y, Cao W, Liu Y, Wang Y, Lang R, Yue Y. Changes in duration of action of rocuronium following decrease in hepatic blood flow during pneumoperitoneum for laparoscopic gynaecological surgery. BMC Anesthesiol. 2017;17(1):45.CrossRefPubMedPubMedCentral

Brill MJ, van Rongen A, van Dongen EP, van Ramshorst B, Hazebroek EJ, Darwich AS, et al. The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery. Pharm Res. 2015;32(12):3927–36.CrossRefPubMedPubMedCentral

Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(13):27–35.CrossRefPubMed

Thummel KE, O’Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59(10):491–502.CrossRefPubMed

Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002;72(8):718–28.CrossRefPubMed

Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51(24):715–28.CrossRefPubMed

10.

Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994;47(9):1643–53.CrossRefPubMed

11.

Shord SS, Chan LN, Camp JR, Vasquez EM, Jeong HY, Molokie RE, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol. 2010;69(2):160–6.CrossRefPubMedPubMedCentral

12.

van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997;44(5):487–93.CrossRefPubMedPubMedCentral

Titel: Author’s Reply to Reith: “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”
verfasst von: Anne van Rongen
Johannes N. van den Anker
Catherijne A. J. Knibbe
Publikationsdatum: 23.06.2018
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 10/2018
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-018-0692-z

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Author’s Reply to Reith: “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”

Excerpt

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses

Comment on van Rongen et al., “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”

Complex Drug–Drug–Gene–Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives

Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives

Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug–Drug Interactions Involving Enzyme Modulation